Summarized by Masters of Longevity from Longevity Technology.
A mitochondria-targeting small molecule is entering Parkinson’s trials while eye‑tracking biomarkers are being deployed to detect subtle functional change across multisite studies.
Key Takeaways
- Mission Therapeutics is advancing MTX325, a brain‑penetrant USP30 inhibitor, into a Phase Ib Parkinson’s patient trial.
- Phase Ia data showed MTX325 reaches the brain based on cerebrospinal fluid sampling and brain imaging.
- NeuraLight will supply AI-driven eye‑movement biomarkers to improve sensitivity and objectivity across multinational trial sites.
